Skip to main
INSM

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 56%
Buy 39%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Insmed Inc. has demonstrated a strong launch trajectory for its commercial products, particularly Brinsupri, which is projected to achieve peak sales potential of over $9 billion in the near term, supported by positive feedback from healthcare professionals. The company has also reported consistent revenue growth for its product Arikayce, with a year-over-year increase of 19%, reinforcing its global expansion efforts and contributing to a total revenue guidance range of $450-$470 million for 2026. With the recent acceleration in Brinsupri sales, Insmed appears well-positioned to reach cash flow positivity without the need for additional capital, alleviating concerns regarding investor dilution.

Bears say

Insmed Inc has faced significant setbacks, notably the failure of brensocatib in the Phase 2b BiRCh study, which has caused a reduction in market expectations and the removal of CRSsNP sales from projections. Key concerns include potential deceleration in Brinsupri sales, a reset of out-of-pocket costs impacting prescription volumes, and the risk of missed endpoints in upcoming clinical trials, particularly in the ENCORE Phase 3 study and the CEDAR Phase 2b trial. Additionally, ongoing challenges in successfully executing clinical trials for Arikayce, brensocatib, and TPIP, coupled with high cash burn rates, could adversely impact Insmed’s overall financial stability and valuation.

Insmed (INSM) has been analyzed by 18 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 39% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Buy based on their latest research and market trends.

According to 18 analysts, Insmed (INSM) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $196, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $196, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.